Parabilis Medicines Analyst Price Targets - Benzinga

Parabilis Medicines Inc

PBLSNASDAQ

Trade with Public

Trade with Public

$36.32

-2.44-6.3%

At close: Sep 10, 5:00 PM EST

$37.03

0.711.95%

After Hours: 4:39 PM EST

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Parabilis Medicines Analyst Price Targets

Wall Street analyst price targets and consensus rating for Parabilis Medicines (PBLS).

Price Target Range — 1 Quarters

Analyst Consensus — 3 Analysts

3Buy

Consensus RatingBuy# Analysts3Avg. Consensus PT$42Upside to Avg. PT+12.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jul 6, 2026	Leerink Partners	Andrew Berens	Initiate	Outperform	$40
Jul 6, 2026	Guggenheim	Michael Schmidt	Initiate	Buy	$40
Jul 6, 2026	B of A Securities	Tazeen Ahmad	Initiate	Buy	$45

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Leerink Partners Initiates Coverage On Parabilis Medicines with Outperform Rating, Announces Price Target of $40

Leerink Partners analyst Andrew Berens initiates coverage on Parabilis Medicines (NASDAQ:PBLS) with a Outperform rating and announces Price Target of $40.

Benzinga Newsdesk

This Parabilis Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Top Wall Street analysts changed outlook on top stocks. See full analyst rating changes & buy/sell recommendations for PBLS stock on Benzinga.

Avi Kapoor

PRO
B of A Securities Initiates Coverage On Parabilis Medicines with Buy Rating, Announces Price Target of $45

B of A Securities analyst Tazeen Ahmad initiates coverage on Parabilis Medicines (NASDAQ:PBLS) with a Buy rating and announces Price Target of $45.

Benzinga Newsdesk